ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle,
WA 98102-3702
United States - Map
Phone: 206-442-6600
Fax: 206-442-6608
Web Site: http://www.zymogenetics.com
| ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The companys product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein, which is in Phase Ib clinical trials for the treatment of viral infections and autoimmune diseases; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases. Its out-licensed product candidates include atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; Augment Bone Graft for orthopedic fracture and other bone defects; rFactor XIII for congenital factor XIII deficiency, cardiac surgery, and cancer related bleeding; Fibroblast growth factor-18 for osteoarthritis; IL-17 receptor C for inflammatory diseases; and IL-20 and IL-22 receptor subunit alpha for psoriasis. The company also offers out-licensed commercial products comprising Novolin and insulin analogs for diabetes; NovoSeven for the treatment of hemophilia; Regranex for wound healing; GEM 21S for periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor for treatment of myocardial infarction. ZymoGenetics has collaboration agreements with Bayer Schering Pharma AG; Bristol-Myers Squibb Company; and Merck Serono S.A. The company was founded in 1981 and is headquartered in Seattle, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Douglas Edward Williams Ph.D., 50
Chief Exec. Officer |
$
622.00K |
$
0 | Mr. James A. Johnson ,
Chief Financial Officer, Exec. VP, Sec. and Treasurer |
$
475.00K |
$
0 | Mr. Stephen W. Zaruby ,
Pres |
N/A
| N/A | Ms. Suzanne Shema J.D., 51
Sr. VP and Gen. counsel |
N/A
| N/A | Dr. Eleanor L. Ramos M.D.,
Chief Medical Officer and Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.06% Nasdaq 
Profile
